Y-Intercept (HK)’s Belite Bio BLTE Stock Holding History

Y-Intercept (HK)’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,152	Closed	-$504K	–	1573
2025 Q4	$504K	Buy	+3,152	New	+$373K	0.01%	1235

Other funds holding BLTE

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Y-Intercept (HK)'s BLTE Position: Q1 2026 in Review

Y-Intercept (HK) sold out of Belite Bio (BLTE) in Q1 2026, closing a stake of 3,152 shares — an estimated $504K sold.

Y-Intercept (HK) first reported a position in BLTE in Q4 2025 and held it in 1 quarter. The position peaked at $504K in Q4 2025. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

Y-Intercept (HK) reported no remaining Belite Bio position as of Q1 2026 after selling out during the quarter.
Y-Intercept (HK) sold 3,152 Belite Bio shares in Q1 2026, an estimated $504K.
Y-Intercept (HK) first reported a position in Belite Bio in Q4 2025 and held it in 1 quarter.
Y-Intercept (HK)'s Belite Bio position peaked at $504K in Q4 2025.
75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Y-Intercept (HK)'s 13F filing for Q1 2026, filed 27 Apr 2026.